Keywords: reopro, found, safer, merck, aggrastat, new, study
J&J's ReoPro found to be safer than Merck's Aggrastat, new study reveals
Article | 17 November 2000
Johnson & Johnson's glycoprotein IIb/IIIa inhibitor ReoPro (abciximab)has won a showdown with Merck & Co's competing drug Aggrastat (tirofiban), according ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
